Greater Improvements Seen for Almost All Secondary Efficacy Measures with FSC vs. Placebo

SFCA3007 SFCA3006

Measure FSC250/50 FSC500/50

TDI (dyspnea)

CRDQ (QOL)

CBSQ (cough/sputum)

PEF ? ?

NT awakenings ? ?

Ventolin use ? ?

Time to COPD exac — —

= statistically significantly different than placebo

• = P=0.05, FP vs. Placebo

— = Pɬ.05, FP vs. Placebo

*

*

*

*

*

*

*

Previous slide

Next slide

Back to first slide

View graphic version